Article
bit.bio appoints Dr Emma Pepperell as Chief Executive Officer
bit.bio appoints Dr Emma Pepperell as Chief Executive Officer
12.06.2026News
News
bit.bio sets out bold vision to power “radical change in drug discovery” at The Human Cell Forum 2026
bit.bio outlines a transformative vision for drug discovery at The Human Cell Forum, emphasising the need for human cell-based mod...
News
bit.bio accelerates global access to human cells with new pricing model and distribution hub
bit.bio lowers ioCells pricing and opens EU hub with next-day delivery, expanding global access to human cells for NAMs research.
News
bit.bio secures $50 million Series C to scale human cell programming technology
bit.bio, Cambridge-based pioneer in next-generation human cell programming, has successfully closed a $50 million Series C funding...
News
bit.bio Publishes 2025 Sustainability Report
bit.bio, the global leader in cell programming technology, today announces the publication of its 2025 Corporate Sustainability R...
News
bit.bio launches Early Access programme for ioHepatocytes, a new iPSC-derived liver model
bit.bio launches Early Access for ioHepatocytes for disease and drug studies with consistent, functional human iPSC-derived hepato...
Press Release
bit.bio Raises $30 Million Led by M&G Investments
Focus on Tools for the Research, Drug Discovery and Cell Therapy Markets.
Press Release
bit.bio launches first-of-their-kind human iPSC-derived cells for gene activation and interference, expanding functional genomics product range
Modulate gene activity in human iPSC-derived cells with a set of CRISPR-ready tools for gene knockout, activation, and interferenc...
Press Release
bit.bio Launches ioTracker Cells Range at SLAS 2025
Adding New Visualisation Functionality to Human iPSC-derived Cell Types